Inventor · disambiguated record
Paul Flynn
Also filed as: FLYNN PAUL · FLYNN PAUL MARY
12 granted patents·8 pending applications·270 citations·filing 1999–2024
90Inventor score
Top patents by PatentIndex Score
20 records- 0197US6846440B2Polyester resin compositions for calenderingEASTMAN CHEM CO·Filed 2002·Granted Jan 25, 2005·142 cites·19 claims
- 0295US11530231B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Granted Dec 20, 2022·5 cites·21 claims
- 0393US11034710B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 15, 2021·7 cites·28 claims
- 0492US6068910APolyester resin compositions for calenderingEASTMAN CHEM CO·Filed 1999·Granted May 30, 2000·77 cites·32 claims
- 0591US6551699B1Polyester resin compositions for calenderingEASTMAN CHEM CO·Filed 2000·Granted Apr 22, 2003·35 cites·5 claims
- 0682US2024173319A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0780US11013741B1AXL kinase inhibitors and use of the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted May 25, 2021·1 cites·11 claims
- 0880US2023390288A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 0979US2025197432A1CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of CancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2024·Application pending·0 cites
- 1077US2023181586A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 1176US12077554B2CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancerSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Granted Sep 3, 2024·0 cites·20 claims
- 1276US11040038B2Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 22, 2021·1 cites·11 claims
- 1372US7438841B2Polyester resin compositions for calenderingEASTMAN CHEM CO·Filed 2007·Granted Oct 21, 2008·1 cites·26 claims
- 1468US2023000864A1Solid dose pharmaceutical compositionSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
- 1568US2023165857A1Axl kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1668US2023233557A1Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2022·Application pending·0 cites
- 1763US11471456B2Formulations comprising heterocyclic protein kinase inhibitorsSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Oct 18, 2022·0 cites·23 claims
- 1862US11400091B2AXL kinase inhibitors and use of the sameSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Aug 2, 2022·0 cites·36 claims
- 1956US7279123B2Polyester resin compositions for calenderingEASTMAN CHEM CO·Filed 2004·Granted Oct 9, 2007·1 cites·19 claims
- 2048US2022380348A1Axl inhibitor formulationsSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →